Immunosuppressive tumor microenvironments can restrain antitumor immunity, particularly in pancreatic ductal adenocarcinoma (PDA). Because CD40 activation can reverse immune suppression and drive antitumor T cell responses, we tested the combination of an agonist CD40 antibody with gemcitabine chemotherapy in a small cohort of patients with surgically incurable PDA and observed tumor regressions in some patients. We reproduced this treatment effect in a genetically engineered mouse model of PDA and found unexpectedly that tumor regression required macrophages but not T cells or gemcitabine. CD40-activated macrophages rapidly infiltrated tumors, became tumoricidal, and facilitated the depletion of tumor stroma. Thus, cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, our findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer.

The E2A gene products, E12 and E47, are critical for proper early B-cell development and commitment to the B-cell lineage. Here we reveal a new role for E2A in T-lymphocyte development. Loss of E2A activity results in a partial block at the earliest stage of T-lineage development. This early T-cell phenotype precedes the development of a T-cell lymphoma which occurs between 3 and 9 months of age. The thymomas are monoclonal and highly malignant and display a cell surface phenotype similar to that of immature thymocytes. In addition, the thymomas generally express high levels of c-myc. As assayed by comparative genomic hybridization, each of the tumor populations analyzed showed a nonrandom gain of chromosome 15, which contains the c-myc gene. Taken together, the data suggest that the E2A gene products play a role early in thymocyte development that is similar to their function in B-lineage determination. Furthermore, the lack of E2A results in development of T-cell malignancies, and we propose that E2A inactivation is a common feature of a wide variety of human T-cell proliferative disorders, including those involving the E2A heterodimeric partners tal-1 and lyl-1.The E2A gene encodes two basic helix-loop-helix (HLH) transcription factors, E12 and E47 (32). E12 and E47, members of the class I HLH proteins, are characterized by their broad expression pattern and their ability to bind DNA either as homodimers or as heterodimers with tissue-specific HLH proteins (9,22,33,40,43). Class I HLH proteins share several highly conserved domains. The HLH domain mediates homoand/or heterodimerization, and the basic region constitutes the sequence-specific DNA binding domain (11,22,32,50). In addition, two distinct domains located in the N-terminal portion of the class I HLH proteins have been shown to be required for transactivation (1,26,39).E12 and E47 arise through differential splicing to the exon that encodes for the HLH domain. Within the HLH domain, their amino acid sequences differ by 20% (32). Both E12 and E47 have the ability to form heterodimers with class II HLH members, including the myogenic regulators (9, 23). However, E12 and E47 have distinct biochemical properties. E47 homodimers bind with high affinity to DNA, whereas an inhibitory domain present in E12 prevents those homodimers from high-affinity DNA binding (46).E2A polypeptides bind to E-box sites present in a wide variety of tissue-specific enhancers, including the insulin, muscle creatine kinase, and immunoglobulin (Ig) intronic and 3Ј enhancers (16,22,28,32,35,38,52). In B cells, it is homodimers of the E2A gene products that bind to E2-box sites present in the Ig enhancers (2,34,43). That E2A gene products play a crucial role in B lymphocyte development has been demonstrated recently by the generation of E2A-deficient mice and transgenic mice overexpressing Id1, an inhibitor of E2A (3,47,56). In the absence of E2A activity, even the earliest committed B-cell precursors are undetectable in the bone marrow (3,47,56). In addition, E2A-deficient mice l...

A fine balance between rates of proliferation and apoptosis in the skin provides a defensive barrier and a mechanism for tissue repair after damage. Vgamma3(+) dendritic epidermal T cells (DETCs) are primary modulators of skin immune responses. Here we show that DETCs both produce and respond to insulin-like growth factor 1 (IGF-1) after T cell receptor stimulation. Mice deficient in DETCs had a notable increase in epidermal apoptosis that was abrogated by the addition of DETCs or IGF-1. Furthermore, DETC-deficient mice had reduced IGF-1 receptor activation at wound sites. These findings indicate critical functions for DETC-mediated IGF-1 production in regulating skin homeostasis and repair.

It is becoming increasingly evident that radiotherapy may benefit from coincident or subsequent immunotherapy. In this study, we examined whether the antitumor effects of radiotherapy, in established triple-negative breast tumors could be enhanced with combinations of clinically relevant monoclonal antibodies (mAb), designed to stimulate immunity [anti-(a)-CD137, a-CD40] or relieve immunosuppression [a-programmed death (PD)-1]. While the concomitant targeting of the costimulatory molecules CD137 and CD40 enhanced the antitumor effects of radiotherapy and promoted the rejection of subcutaneous BALB/c-derived 4T1.2 tumors, this novel combination was noncurative in mice bearing established C57BL/6-derived AT-3 tumors. We identified PD-1 signaling within the AT-3 tumors as a critical limiting factor to the therapeutic efficacy of a-CD137 therapy, alone and in combination with radiotherapy. Strikingly, all mice bearing established orthotopic AT-3 mammary tumors were cured when a-CD137 and a-PD-1 mAbs were combined with single-or low-dose fractionated radiotherapy. CD8 þ T cells were essential for curative responses to this combinatorial regime. Interestingly, CD137 expression on tumor-associated CD8 þ T cells was largely restricted to a subset that highly expressed PD-1.